Clinical Trials Logo

Hematoma clinical trials

View clinical trials related to Hematoma.

Filter by:

NCT ID: NCT05079295 Recruiting - Clinical trials for Chronic Subdural Hematoma

Management of Anticoagulants and Antithrombotics in Patients With CSDH

THERCA
Start date: February 20, 2021
Phase:
Study type: Observational

Primary objective of the study will be to compare, up to 6 months after surgery, number of relapses (post operative re-bleeding) or intracerebral hemorrhage (others than subdural hematomas) and thromboembolic or cardiovascular ischemic events, in patients undergoing surgery for chronic subdural hematoma (CSDH). These data will be correlated to the suspension or not of antithrombotics or anticoagulants before surgery or their re-introduction after surgery.

NCT ID: NCT05038930 Recruiting - Clinical trials for Subarachnoid Hemorrhage

Mobilising Patients With Severe Brain Injury in Intensive Care

MAWERIC
Start date: October 1, 2021
Phase: N/A
Study type: Interventional

Introduction Patients with severe brain injury are often restricted to bed rest during the early period of brain injury which may lead to unwanted secondary complications. There is lack of evidence of when to initiate the first mobilisation. The Sara Combilizer® is an easy and efficient tool for mobilising patients with severe injuries, including brain injury. Through a randomised cross-over trial the investigators will investigate the impact of early mobilisation on patients with severe acquired brain injury caused by traumatic brain injury, subarachnoid brain injury or intracranial haematoma. The investigators hypothesise that mobilisation using the Sara Combilizer® does not affect partial oxygenation of brain tissue.

NCT ID: NCT05030740 Active, not recruiting - Clinical trials for Dissection of Thoracic Aorta

French Assessment of the Relay Plus and Relay NBS Plus Thoracic Stent-Graft

Start date: December 18, 2014
Phase:
Study type: Observational

Stent treatment of thoracic aortic pathologies, including aneurysms, pseudo-aneurysms, dissections, intramural hematomas, penetrating ulcers and ruptures of the isthmus, seems to provide a likely benefit compared to surgery in terms of surgical mortality and severe morbidity. However, the data concerning the long-term fate of these stents are insufficient. For this reason, the French National Health Authority (HAS) requests a 5-year follow-up in relation to the renewal of insurance reimbursement for these stent-grafts. Therefore, this long-term observational study has been set up.

NCT ID: NCT04966546 Active, not recruiting - Clinical trials for Chronic Subdural Hematoma

Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD)

TASD
Start date: June 1, 2022
Phase: Early Phase 1
Study type: Interventional

Chronic Subdural Hematoma (cSDH) is an extremely common problem, particularly in the aging population, where fluid like collections compress the brain, frequently requiring surgical drainage. After drainage, 25-50% of patients experience post operative neurologic deficits such as weakness or confusion that are often not explained by problems such as seizure, stroke, or mass effect from the fluid and blood. Recent subdural recordings have demonstrated that some of these neurological deficits may be related to waves of spreading depolarization (SD), which cause temporary neurological dysfunction. Our overall objective is to examine the relationship between neurological deficits and SD and to assess feasibility of a pilot trial to determine if a strategy of NMDA-R antagonism can effectively reduce SD and improve clinical recovery.

NCT ID: NCT04961424 Completed - Thoracic Surgery Clinical Trials

Risk Factors for Postoperative Spinal Epidural Hematoma Following Posterior Thoracic Spinal Surgery in a Single Institute

Start date: February 19, 2020
Phase:
Study type: Observational

This is a retrospective, observational single-center study. The studies is to investigate the incidence of posterior epidural spinal hematoma(PSEH) and recognize the risk factors for it in a cohort of patients undergoing posterior thoracic surgery in isolation.

NCT ID: NCT04947514 Completed - Clinical trials for Venous Thromboembolism

Use of Tranexamic Acid in Reduction Mammoplasty

TREX-ARM
Start date: October 29, 2021
Phase: Phase 4
Study type: Interventional

Breast reduction mammoplasty (BRM) is among the most commonly performed procedures in plastic surgery. However, postoperative hematoma is one of the most common complications following BRM. Hematoma-related complications include unplanned surgery, need for blood transfusion, wound healing issues, and unfavorable surgical outcomes. Tranexamic acid has emerged in the literature as a promising agent that reduces perioperative blood loss and need for transfusion. However, despite its consistently reported efficacy, low cost, and favorable safety profile, tranexamic acid remains underutilized in plastic surgery. The investigators propose a prospective, double-blinded randomized controlled study of the efficacy of tranexamic acid in reducing hematoma development in patients undergoing reduction mammoplasty. The investigators hope to contribute to the growing body of literature supporting tranexamic acid to reduce unwanted surgical bleeding.

NCT ID: NCT04943783 Recruiting - Clinical trials for Inflammation Vascular

Atorvastatin in the TREATment of Intracranial Unruptured VertebroBasilar Dissecting Aneurysms

ATREAT-VBD
Start date: July 1, 2021
Phase: N/A
Study type: Interventional

This study was designed to whether there is a measurable reduction in inflammation in walls of unruptured vertebrobasilar dissecting aneurysms with atorvastatin.

NCT ID: NCT04923984 Recruiting - Subdural Hematoma Clinical Trials

Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)

EMMA-Can
Start date: May 1, 2021
Phase: N/A
Study type: Interventional

EMMA-Can is a prospective cohort study to assess the safety and effectiveness of MMA-embolization for the treatment of CSDH. Hypothesis- EMMA reduces the recurrence rate of SDH with or without concomitant surgical evacuation.

NCT ID: NCT04918589 Not yet recruiting - Breast Cancer Clinical Trials

Tranexamic Acid for Alloplastic Breast Reconstruction

Start date: August 2022
Phase: Phase 3
Study type: Interventional

Hematoma is a common complication of alloplastic breast reconstruction. This can lead to pain and discomfort experienced by the patient, in addition to greater use of valuable healthcare resources. Previous studies have shown correlation between the use of tranexamic acid (TXA), an anti-fibrinolytic, and reduced post-surgical bleeding complication events. In this randomized control trial (RCT) assessing TXA use in alloplastic breast reconstruction, one breast will be randomized to have TXA applied topically, while the other will have normal saline (NS) placebo applied. The primary objective of this prospective blinded randomized control trial study is to determine if the administration of topical TXA in alloplastic breast reconstruction reduces the incidence of surgical site hematoma compared to placebo within 2 weeks following surgery. The results of this study will be used to inform the design of a larger multicentered RCT on TXA in breast surgery.

NCT ID: NCT04918576 Not yet recruiting - Tranexamic Acid Clinical Trials

Topical Tranexamic Acid for Bilateral Breast Reduction Surgery

Start date: August 2022
Phase: Phase 3
Study type: Interventional

Hematoma is a common complication of bilateral breast reduction (BBR) surgery. This can lead to pain and discomfort experienced by the patient, in addition to greater use of valuable healthcare resources. Previous studies have shown correlation between the use of tranexamic acid (TXA), an anti-fibrinolytic, and reduced post-surgical bleeding complication events. In this randomized control trial (RCT) evaluation TXA use in BBR, for which one breast will be randomized to have TXA applied topically, while the other will have normal saline (NS) placebo applied. The primary objective of this prospective blinded randomized control trial study is to determine if the administration of topical TXA in BBR reduces the incidence of surgical site hematoma compared to placebo within 2 weeks following surgery. The results of this study will be used to inform the design of a larger multicentered RCT on TXA in breast surgery.